Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Jury Sides With Endo And Impax On 2014 Opana Antitrust Suit

Opana ER Purchasers Claimed $102m Endo Payment ‘Effectively Guaranteed’

Executive Summary

Endo and Impax have received a favorable jury verdict after a 2010 patent-litigation settlement between the pair over Endo’s Opana ER was alleged to have been “an anticompetitive scheme that restrained competition,”

You may also be interested in...

FTC v. Endo: Exclusive Licenses, ‘Supracompetitive Prices’ Are Protected By Patent Laws

In an unsealed redacted opinion dismissing FTC’s complaint, district judge says Endo’s agreement with Impax, which left it the sole marketer of oxymorphone ER, falls within the bounds of anticompetitive activity protected by patent laws.

US Supreme Court Reignites Claims Government Overcharged Millions For Generics

In a case that could have significant ramifications for the scope of the US False Claims Act, the US Supreme Court has agreed to remand for further proceedings allegations that supermarket and pharmacy chains defrauded the government via low-cost drug programs.

Sandoz Reveals New Headquarters Post Spin, Mid-2024 Date Outlined

Tracing its roots back to Basel in the late nineteenth century, Sandoz has confirmed the location of its new planned permanent headquarters post-spin.


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts